What We Do
Target ALS launched the Innovation Ecosystem to identify, support, and accelerate the translation of the most promising ideas into the clinic.
Six components power the Innovation Ecosystem ecosystem including collaborative funding opportunities, accessible tools and resources, and abundant opportunities to network and communicate with fellow scientists.
Target ALS brings together academic and industry investigators from a range of disciplines including high-throughput functional genomics, protein homeostasis, and medicinal chemistry to accelerate progress. Over the last six years, we have supported the development of over 100 unique collaborations including 31 funded consortia.
Target ALS has developed a range of new tools and resources to assist scientists in discovery, validation and development of therapeutic target candidates and candidate biomarkers.
How We Make Decisions
To maximize our impact, Target ALS does not seek intellectual property (IP) or other forms of ownership stemming from the use of its resources or funding. To ensure that the funds are administered in a time-effective and transparent manner, we have established a structure that clearly identifies roles in defining and approving overall strategy through our Board and Independent Review Committee (IRC). Evaluation and determination of all funding is through the IRC, which ensures our grant-making is free of the politics and bias sometimes found in philanthropy
Conflict of interest issues are addressed by our Conflict of Interest Committee. Our Target ALS Team handles execution. To ensure that all decisions are made fairly and to remove any conflict of interest, we have established a strict Conflict of Interest (COI) policy whose compliance is ensured by the COI Committee. This committee not only monitors all Target ALS operations, but it also serves as a platform for any issues brought up by the ALS research community.